self pay semaglutide Novo Nordisk unveils $499 cash-pay Ozempic offering Novo Nordisk launches introductory self-pay

Wall Street analysts project that the market for GLP-1, the class of drug that Ozempic belongs to, will reach $105 billion by 2030

Liraglutide has been approved by the United States Food and Drug Administration (FDA) for long-term weight management (4)

In rat studies, ipamorelin produced dose-dependent body weight increases alongside the bone growth effects, suggesting anabolic activity beyond skeletal tissue (Johansen et al., 1999)

GLP-1 receptor agonist as treatment for cancer as well as diabetes: Beyond blood glucose control

Oral administration of Dihexa achieves 4060% bioavailability with slower absorption kinetics compared to subcutaneous injection, potentially reducing the need for daily dosing due to sustained plasma concentrations